Interim Report 2026
Filed with HKEX · Stock code 2190 · · 95 pages · English
Summary by 6ix AI
The report highlights a significant increase in revenue and profit compared to the same period last year, driven by strong sales growth in both neurovascular and peripheral vascular interventional products. The company emphasizes its commitment to innovation and global expansion, showcasing new product launches and strategic acquisitions to enhance market presence. Overall, the report reflects the company's robust growth strategy and operational efficiency in the competitive medical device market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zylox-Tonbridge Medical Technology Co., Ltd. on 6ix
Earlier from Zylox-Tonbridge Medical Technology
- Zylox-Tonbridge Delivers Strong First-Half 2026 Results as International Revenue Surges 349%
- Zylox-Tonbridge Recognized as Most Honored Company in Extel 2026 Asia Executive Team Survey
- Zylox-Tonbridge Reports 2025 Annual Results with Revenue Exceeding RMB 1.06 Billion and Net Profit Up 143.7% Year-over-Year
- Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
- Zylox-Tonbridge Hosts Investor Open Day, Showcasing Innovation Pipeline and Global Growth Strategy
Later from Zylox-Tonbridge Medical Technology
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Discloseable transaction in relation to the proposed acquisition of equity interest in the target company and the proposed issue of new h shares under the general mandate
Follow Zylox-Tonbridge Medical Technology into a list and get an email when it puts out news.
Follow Zylox-Tonbridge Medical Technology